Spark Investment Management LLC boosted its holdings in shares of Arvinas Inc (NASDAQ:ARVN) by 91.9% in the 1st quarter, HoldingsChannel.com reports. The firm owned 35,500 shares of the company’s stock after purchasing an additional 17,000 shares during the quarter. Spark Investment Management LLC’s holdings in Arvinas were worth $523,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other large investors have also made changes to their positions in ARVN. Strs Ohio bought a new stake in shares of Arvinas in the 4th quarter worth approximately $26,000. American International Group Inc. bought a new stake in shares of Arvinas in the 4th quarter worth approximately $66,000. Deutsche Bank AG bought a new stake in shares of Arvinas in the 4th quarter worth approximately $135,000. Diag Capital Management LP bought a new stake in shares of Arvinas in the 4th quarter worth approximately $311,000. Finally, Geode Capital Management LLC bought a new stake in shares of Arvinas in the 4th quarter worth approximately $846,000. Hedge funds and other institutional investors own 41.78% of the company’s stock.
In related news, Director Timothy M. Shannon bought 3,500 shares of the company’s stock in a transaction dated Thursday, March 28th. The stock was acquired at an average cost of $14.69 per share, with a total value of $51,415.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, major shareholder Ventures Iii L.P. 5Am sold 361,129 shares of the stock in a transaction that occurred on Thursday, March 28th. The stock was sold at an average price of $14.16, for a total value of $5,113,586.64. The disclosure for this sale can be found here. 31.77% of the stock is currently owned by company insiders.
Shares of ARVN stock opened at $22.16 on Thursday. The company has a quick ratio of 8.73, a current ratio of 8.73 and a debt-to-equity ratio of 0.03. Arvinas Inc has a 12 month low of $10.19 and a 12 month high of $25.61. The company has a market capitalization of $728.96 million and a price-to-earnings ratio of -0.87.
Arvinas (NASDAQ:ARVN) last announced its quarterly earnings data on Wednesday, May 8th. The company reported ($0.46) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.46). The firm had revenue of $4.02 million during the quarter, compared to the consensus estimate of $3.50 million. On average, equities research analysts forecast that Arvinas Inc will post -2.03 EPS for the current year.
A number of analysts have commented on ARVN shares. Zacks Investment Research downgraded Arvinas from a “hold” rating to a “sell” rating in a research report on Thursday, April 25th. Piper Jaffray Companies raised their price objective on Arvinas from $23.00 to $32.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 8th. Finally, Evercore ISI started coverage on Arvinas in a research report on Thursday, April 11th. They issued an “outperform” rating for the company. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $23.33.
COPYRIGHT VIOLATION NOTICE: “Arvinas Inc (ARVN) Position Increased by Spark Investment Management LLC” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2019/05/23/arvinas-inc-arvn-position-increased-by-spark-investment-management-llc.html.
Arvinas, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110, proteolysis targeting chimeras (PROTAC) that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of women with metastatic ER positive/HER2 negative breast cancer.
Further Reading: How to trade on quiet period expirations
Want to see what other hedge funds are holding ARVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arvinas Inc (NASDAQ:ARVN).
Receive News & Ratings for Arvinas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arvinas and related companies with MarketBeat.com's FREE daily email newsletter.